Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis

201825 citationsJournal Articlegold Open Access

Authors

Suliman Al‐Fayoumi · CTI BioPharma (United States)

Taishi Hashiguchi · SMC Corporation (Japan)

Yuka Shirakata · SMC Corporation (Japan)

John Mascarenhas · Icahn School of Medicine at Mount Sinai

Jack W. Singer · CTI BioPharma (United States)

Abstract

These results, the first to demonstrate hepatic antifibrotic effects for pacritinib in an animal model of liver disease, provide preliminary support for potential clinical applications of pacritinib in fibrotic diseases other than myelofibrosis.

Topics & Keywords

Chronic Myeloid Leukemia Treatments Liver physiology and pathology Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Experimental Pharmacology

Volume Volume 10, pp. 9-17

DOI: 10.2147/jep.s150729

Field-Weighted Citation Impact: 1.31